Johnson & Johnson (NYSE:JNJ) Shares Acquired by Roman Butler Fullerton & Co.
Roman Butler Fullerton & Co. lifted its stake in Johnson & Johnson (NYSE:JNJ) by 7.1% in the 2nd quarter, Holdings Channel reports. The firm owned 11,742 shares of the company’s stock after purchasing an additional 783 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of Roman Butler Fullerton & Co.’s portfolio, making the stock its 19th biggest position. Roman Butler Fullerton & Co.’s holdings in Johnson & Johnson were worth $1,651,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in JNJ. Capital World Investors lifted its position in shares of Johnson & Johnson by 182.9% during the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock valued at $2,779,435,000 after acquiring an additional 13,703,905 shares during the period. Wellington Management Group LLP increased its stake in Johnson & Johnson by 10.8% in the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after purchasing an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in Johnson & Johnson by 7.7% during the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after purchasing an additional 2,118,870 shares during the last quarter. Capital International Investors boosted its position in Johnson & Johnson by 13.6% during the first quarter. Capital International Investors now owns 16,726,965 shares of the company’s stock worth $2,193,411,000 after purchasing an additional 2,004,688 shares in the last quarter. Finally, Swiss National Bank boosted its position in Johnson & Johnson by 21.9% during the first quarter. Swiss National Bank now owns 11,147,766 shares of the company’s stock worth $1,461,807,000 after purchasing an additional 2,003,900 shares in the last quarter. 68.44% of the stock is currently owned by hedge funds and other institutional investors.
Several research firms have recently issued reports on JNJ. UBS Group downgraded Johnson & Johnson from a “buy” rating to a “neutral” rating and cut their price target for the stock from $163.00 to $160.00 in a research note on Tuesday, April 28th. ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, July 15th. Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 price target on shares of Johnson & Johnson in a research report on Tuesday, April 28th. Citigroup lifted their price objective on Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Finally, Wells Fargo & Co upgraded Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $163.38.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The firm had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. During the same period in the previous year, the firm earned $2.58 earnings per share. Johnson & Johnson’s revenue was down 10.8% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 7.85 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What are Institutional Investors?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.